0001410939-22-000040.txt : 20220401 0001410939-22-000040.hdr.sgml : 20220401 20220401190334 ACCESSION NUMBER: 0001410939-22-000040 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220330 FILED AS OF DATE: 20220401 DATE AS OF CHANGE: 20220401 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SBLENDORIO GLENN CENTRAL INDEX KEY: 0001277478 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36080 FILM NUMBER: 22799969 MAIL ADDRESS: STREET 1: 3 TIMES SQAURE, 12TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IVERIC bio, Inc. CENTRAL INDEX KEY: 0001410939 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 208185347 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 8 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: (609) 474-6755 MAIL ADDRESS: STREET 1: 8 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 FORMER COMPANY: FORMER CONFORMED NAME: Ophthotech Corp. DATE OF NAME CHANGE: 20070828 4 1 wf-form4_164885419748372.xml FORM 4 X0306 4 2022-03-30 0 0001410939 IVERIC bio, Inc. ISEE 0001277478 SBLENDORIO GLENN C/O IVERIC BIO, INC. 8 SYLVAN WAY PARSIPPANY NJ 07054 1 1 0 0 CEO Common Stock 2022-03-30 4 M 0 1213 2.94 A 280902 D Common Stock 2022-03-30 4 S 0 1213 17.004 D 279689 D Common Stock 2022-03-31 4 M 0 1400 2.94 A 281089 D Common Stock 2022-03-31 4 S 0 1400 17.02 D 279689 D Common Stock 2022-04-01 4 M 0 40756 2.94 A 320445 D Common Stock 2022-04-01 4 S 0 40756 17.50 D 279689 D Stock Option (right to buy) 2.94 2022-03-30 4 M 0 1213 0 D 2027-12-18 Common Stock 1213.0 367156 D Stock Option (right to buy) 2.94 2022-03-31 4 M 0 1400 0 D 2027-12-18 Common Stock 1400.0 365756 D Stock Option (right to buy) 2.94 2022-04-01 4 M 0 40756 0 D 2027-12-18 Common Stock 40756.0 325000 D The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021, and as described in the Registrant's Proxy Statement for its 2022 Annual Meeting of the Stockholders, as filed with the Securities and Exchange Commission on March 30, 2022. The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $17.00 to $17.01 per share on March 30, 2022. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range. The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $17.00 to $17.02 per share on March 31, 2022. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range. The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $17.00 to $17.83 per share on April 1, 2022. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range. This stock option award was granted on December 19, 2017 and vested with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date. /s/ Todd Anderman, as Attorney-in-Fact for Glenn P. Sblendorio 2022-04-01